发明名称 |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
摘要 |
Erodible, gastric-retentive dosage forms are provided that are formulated using the in vitro drug release profile obtained with USP Disintegration test equipment rather the USP Dissolution Apparatus. The invention is premised on the discovery that the USP Disintegration Test and modified versions thereof are far more predictive of the in vivo release profile for a controlled release dosage form than is the standard USP Dissolution Test, particularly controlled release dosage forms of the swellable, erodible type. The dosage forms generally comprise particles of a biocompatible, hydrophilic polymer having the active agent incorporated therein, wherein the particles are optionally but preferably compacted into a tablet or loaded into a capsule. The dosage forms can be used to deliver water-insoluble or sparingly soluble drugs as well as water-soluble drugs, providing that the latter are coated with a protective coating or contained in a protective vesicle.
|
申请公布号 |
US2003091630(A1) |
申请公布日期 |
2003.05.15 |
申请号 |
US20010014750 |
申请日期 |
2001.10.25 |
申请人 |
LOUIE-HELM JENNY;BERNER BRET |
发明人 |
LOUIE-HELM JENNY;BERNER BRET |
分类号 |
A61K47/32;A61K9/00;A61K9/127;A61K9/20;A61K9/22;A61K9/50;A61K9/51;A61K31/155;A61K31/337;A61K31/341;A61K31/35;A61K31/351;A61K31/36;A61K31/496;A61K31/616;A61K31/635;A61K33/00;A61K47/34;A61K47/36;A61K47/38;A61K49/04;A61P1/04;A61P3/10;A61P7/10;A61P13/02;A61P25/08;A61P33/04;A61P35/00;(IPC1-7):A61K9/22;A61K9/14 |
主分类号 |
A61K47/32 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|